Abstract:Objectives This prospective cohort study tested for associations between baseline cognitive performance in individuals early within their first episode and antipsychotic treatment of psychosis. We hypothesised that poorer cognitive functioning at the initial assessment would be associated with poorer antipsychotic response following the subsequent 6 weeks. Design Prospective cohort . Setting National Health Service users with a first-episode schizophrenia diagnosis, recently starting antipsychotic medication, recruited from two UK sites (King's College London, UK and University of Manchester, UK). Participants attended three study visits following screening. Participants Eighty-nine participants were recruited, with 46 included in the main analysis. Participants required to be within the first 2 years of illness onset, had received minimal antipsychotic treatment, have the capacity to provide consent, and be able to read and write in English. Participants were excluded if they met remission criteria or showed mild to no symptoms. Primary and secondary outcome measures Antipsychotic response was determined at 6 weeks using the Positive and Negative Syndrome Scale (PANSS), with cognitive performance assessed at each visit using the Brief Assessment of Cognition in Schizophrenia (BACS). The groups identified (responders and non-responders) from trajectory analyses, as well as from >20% PANSS criteria, were compared on baseline BACS performance. Results Trajectory analyses identified 84.78% of the sample as treatment responsive, and the remaining 15.22% as treatment non-responsive. Unadjusted and adjusted logistic regressions observed no significant relationship between baseline BACS on subscale and total performance (BACS t-score: OR=0.98, p=0.620, Cohen's d=0.218) and antipsychotic response at 6 weeks. Conclusions This investigation identified two clear trajectories of treatment response in the first 6 weeks of antipsychotic treatment. Responder and non-responder groups did not significantly differ on performance on the BACS, suggesting that larger samples may be required or that an association between cognitive performance and antipsychotic response is not observable in the first 2 years of illness onset. Trial registration number REC: 17/NI/0209.

Relationship between changes in metabolic syndrome constituent components over 12 months of treatment and cognitive performance in first-episode schizophrenia

Metabolic Effects Of 7 Antipsychotics On Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial

The Bidirectional Relationship Between Weight Gain and Cognitive Function in First-Episode Schizophrenia: A Longitudinal Study in China

Metabolic risk factors of cognitive impairment in young women with major psychiatric disorder

Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia

Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials

Genetic predisposition and antipsychotic treatment effect on metabolic syndrome in schizophrenia: a ten-year follow-up study using the Estonian Biobank

Metabolic Syndrome Status Changes and Cognitive Functioning: Insights from the Lifelines Cohort Study

The relationship between body mass index and cognitive function among patients with first-ever occurrence of schizophrenia after treatment

Association between increased BMI and cognitive function in first-episode drug-naïve male schizophrenia

The metabolic effects of antipsychotics in the early stage of treatment in first-episode patients with schizophrenia: A real-world study in a naturalistic setting

Improving Cognition to Increase Treatment Efficacy in Schizophrenia: Effects of Metabolic Syndrome on Cognitive Remediation's Outcome

Unveiling the Metabolic Profile of First-Episode Drug-Naïve Schizophrenia Patients: Baseline Characteristics of a Longitudinal Study Among Han Chinese

Cognitive function and treatment response trajectories in first-episode schizophrenia: evidence from a prospective cohort study

Serum Metabolic Profiling Using Small Molecular Water-Soluble Metabolites in Individuals with Schizophrenia: A Longitudinal Study Using a Pre-Post-treatment Design.

Negative symptom resolution and improvements in specific cognitive deficits after acute treatment in first-episode schizophrenia

Longitudinal changes in cognitive function in early psychosis: a meta-analysis with the MATRICS consensus cognitive battery (MCCB)

Association Between Metabolic Risk Factors and Cognitive Impairment in Schizophrenia Based on Sex.

Altered mitochondrial lymphocyte in overweight schizophrenia patients treated with atypical antipsychotics and its association with cognitive function

Metabolic Risk Factors In First-Episode Schizophrenia: Baseline Prevalence And Course Analysed From The European First-Episode Schizophrenia Trial

The relationship of cognitive function and metabolic syndrome in stable schizophrenia patients under long-term olanzapine treatment